Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology USA
    Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUC
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology USA
    Advancing Genomic Competence and Patient Centered Care in Metastatic Breast Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom
    AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction Management
    Release Date:
    Review Process: Pfizer Internal
    Research Internal Medicine Australia, Canada, Germany, Greece, Japan, Korea, Taiwan
    Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-posit
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology United States Minor Outlying I
    OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic Malignancies
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology China
    Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory Outcome
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    Implementing Shared Decision Making in Hemophilia Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease USA
    Transthyretin Cardiac Amyloidosis Fellowship
    Release Date:
    Review Process: Pfizer Internal
    Fellowship Internal Medicine Germany
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Research on Disease Burden of CRE (including non-MBL and MBL-CRE), CR-PA and Stenotrophomonas Maltophilia in China
    Release Date:
    Review Process: Pfizer Internal
    Research Hospital China
    Research on Diagnostic and Treatment of Invasive Mold Disease
    Release Date:
    Review Process: Pfizer Internal
    Research Hospital China
    Optimizing Care for Patients with HR+/HER2- or HER2+ (regardless of hormonal status) metastatic Breast Cancer (mBC)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Spain
    Educational approaches to address immunization practice gaps and improve adult vaccination coverage in Switzerland
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Switzerland
    Improving Patient Care of Lower Respiratory Tract Infection Among Infants
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement Vaccines Thailand
    China Medical Education in Non-small Cell Lung Cancer Diagnosis, Treatment and Long-Term Disease Management
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology China
    Diagnosis and Treatment of Cancer Cachexia
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology France, Germany, Italy, Japan, Spain, USA, United Kingdom
    Healthcare Optimization and Patient Equity for Lung Cancer in China (“HOPE”)
    Release Date:
    Partner: The International Association for the Study of Lung Cancer (IASLC)
    Review Process: Expert Review Panel
    Quality Improvement Oncology China
    Optimizing ER+ Metastatic Breast Cancer Treatment: incorporating emerging treatment options and biomarker testing
    Release Date:
    Partner: Arvinas
    Review Process: Pfizer Internal
    Education Oncology All
    Optimizing vaccination pathways among at-risk or immunocompromised adults and the elderly in Italy​
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement Vaccines Italy
    Expanding Access to Maternal Immunization Resources and Point-of-Care Tools
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    Optimizing ATTR-CM Diagnosis and Care in Heart Failure Patients Quality Improvement Grant Program Request for Proposals
    Release Date:
    Partner: American College of Cardiology
    Review Process: Expert Review Panel
    Quality Improvement Rare Disease USA